Wed, Jun 20, 2018
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Chanos hits Express Scripts, Mallinckrodt Pharmaceuticals in SALT presentation

Friday, May 19, 2017

Bailey McCann, Opalesque New York:

Famed short seller Jim Chanos of Kynikos Associates used his presentation at the SkyBridge Alternative Conference (SALT) along with a separate media Q&A to take the US healthcare system to task and more specifically, announce shorts on Mallinckrodt Pharmaceuticals and Express Scripts.

Mallinckrodt Pharmaceuticals is known for its distribution of the drug Acthar, which is designed to treat spasms in infants. The drug can also be prescribed for several other afflictions and represents both the primary source of revenue for Mallinckrodt and a primary cost driver for Medicare Part D.

According to Chanos, Acthar is the revenue stream for Mallinckrodt. His Express Scripts short is also tied into Acthar, as a handful of Express Scripts subsidiaries are paid to distribute Acthar exclusively. Chanos notes that the cost to patients for Acthar, like many other drugs, is extraordinarily inflated."This alliance may lead to performance enhancing drug prices," Chanos said. "But may give investors the blues."

Business Insider reporter Linnette Lopez recently reported on the suspect relationships surrounding Acthar and Chanos' presentation filled out some additional details. "If you look at Express Scripts 10K, it reads very ominously," Chanos said, highlighting a lawsuit brought by Anthem, one of the largest insurers i......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Lyxor recommends stockpicking strategies, L/S equity hedge funds well equipped for turbulent markets[more]

    Matthias Knab, Opalesque: Market developments in May saw some trend reversals across the fixed income and commodity space. On the one hand, the unfolding of the Italian political crisis coincided with a rebound of U.S. Treasuries during the second half of May. On the other hand, the rising likeli

  2. North America - George Soros: 'Everything that could go wrong has gone wrong'[more]

    From Marketwatch.com: George Soros, tell us how you really feel. 'Everything that could go wrong has gone wrong. [Trump] is willing to destroy the world.' The 87-year-old billionaire clearly isn't shy about expressing his generally liberal views and distaste for Trump's "America First" platform,

  3. Paper: The performance of stocks actively pitched by hedge funds[more]

    Using a novel dataset drawn from investment conferences from 2008 to 2013, I show that hedge funds take advantage of the publicity of these conferences to strategically release their book information to drive market demand. Specifically, hedge funds sell pitched stocks after the conferences to ta

  4. North America - US fundraising for special purpose acquisition vehicles hits record this year[more]

    From AFR.com: Special purpose acquisition vehicles (spacs) are hitting the US market at the fastest rate on record, attracting the likes of Goldman Sachs and hedge fund investor Daniel Loeb for the two largest such deals in 2018. Spacs have raised $US4.5bn so far in 2018, the largest amount fo

  5. Investing - Man Group and AQR try to take aim at private equity industry, Hedge funds poised to be winners in AT&T-Time Warner deal[more]

    Man Group and AQR try to take aim at private equity industry From FT.com: The popularity of private equity investments has prompted asset managers such as Man Group and AQR to devise strategies that aim to replicate PE returns but at a much lower cost to investors. Both companies a